top of page

A Sequential Phase 2/​3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

NCT07213960

Pegcetacoplan is under investigation for the treatment of focal segmental glomerulosclerosis (FSGS), a heterogeneous disorder characterized by histopathological lesions that are associated with glomerular basement membrane dysfunction. These lesions may result in glomerular scarring, proteinuria, and tubular inflammation, and ultimately, end-stage kidney disease. Although the causes underlying the FSGS pattern of injury vary across primary, genetic, and undetermined-cause FSGS, complement activation has been implicated in contributing to further kidney damage.


How is pegcetacoplan being studied in FSGS?

NCT07213960 is a sequential Phase 2/3 study to evaluate the efficacy and safety of pegcetacoplan in patients with FSGS. The initial Phase 2 portion, which is now enrolling, is a single-arm, open-label study in adults with FSGS. Phase 2 will begin before randomization starts for Phase 3. The Phase 3 portion of the study is a randomized, placebo-controlled, double-blinded, global study in adults and adolescents with FSGS.


The Phase 2 portion of this multicenter, open-label study of pegcetacoplan will enroll approximately 15 adults with biopsy-confirmed primary, genetic, or undetermined-cause FSGS from various sites across the US. Participants will self-administer twice-weekly subcutaneous infusions of pegcetacoplan (1080 mg/20 mL).


The planned length of participation in Phase 2 for each participant is a maximum of approximately 120 weeks and will consist of 3 parts:

  • Up to 8-week screening period

  • 104-week open-label period

  • 8-week follow-up period


The primary outcome measure for Phase 2 is log-transformed ratio of urine protein-to-creatinine ratio (UPCR) at Week 12 (and exploratory endpoint at Week 104) compared with baseline, based on triplicate first morning urine (FMU).


Key Eligibility Criteria for Phase 2:

  • Adults (≥ 18 years) with primary, genetic, or undetermined-cause FSGS diagnosed by kidney biopsy

  • Weight ≥ 30 kg and ≤ 120 kg at screening with a body mass index ≤ 40 kg/m2

  • Proteinuria ≥ 1.5 mg/mg on a screening 24-hour urine collection or UPCR of ≥ 1.5 mg/mg in ≥ 2 FMU samples collected during screening

  • Estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2

  • Stable treatment for FSGS (may include renin-angiotensin-aldosterone system [RAAS] inhibitors and/or immunosuppressants) for ≥ 12 weeks with no planned or anticipated adjustments or dose changes to the stable treatment regimen

  • Have received pneumococcal and meningococcal vaccinations as per Advisory Committee on Immunization Practices (ACIP) recommendations prior to initiating trial treatment and, if required, have received approved antibiotic prophylaxis

  • No history of kidney transplant


Link to Study Website

https://clinicaltrials.gov/study/NCT07213960

Laptop and Phone

Enroll in this study

Apellis (now part of Biogen) Clinical Trial Information Line 833-284-6361 clinicaltrials@apellis.com

bottom of page